Millennium Pharmaceuticals, Inc. (South San Francisco, California) VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported the presentation of results of a randomized Phase III trial that investigated the effect of consolidation with single-agent VELCADE® (bortezomib) for Injection in newly diagnosed multiple myeloma (MM) patients after autologous stem cell transplant (ASCT). The study showed that consolidation with VELCADE led to significant improvements in response rates and progression-free survival, while the overall survival rate was 87 percent in both arms after a median follow-up of 27 months. These data were presented at the 13th International Myeloma Workshop, held May 3-6 in Paris, France.